HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

FDA Grants Trastuzumab Deruxtecan Priority Review for HER2+ Breast Cancer

October 17th 2019

The FDA has granted a priority review designation to a biologics license application for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast Cancer

October 16th 2019

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer

October 14th 2019

Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.

Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast Cancer

October 9th 2019

Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Lead KATE2 Author Suggests Atezolizumab Benefits HER2+ Breast Cancer Subgroup

October 8th 2019

Leisha A. Emens, MD, PhD, discusses the rationale behind the KATE2 study and the results that may signal clinical significance.

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain Metastases

October 8th 2019

Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discusses the use of neratinib (Nerlynx) and capecitabine in patients with HER2-positive breast cancer that has metastasized to the brain.

Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer

October 5th 2019

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

Updated HER2+ Breast Cancer Guidelines Offer Additional Insight, But Questions Remain

October 4th 2019

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

FDA Updates Neratinib Label in HER2+ Breast Cancer

October 3rd 2019

The FDA has approved a labeling supplement for neratinib for the extended adjuvant treatment of patients with HER2-positive early-stage breast cancer.

Examining Major Breakthroughs Made in Breast Cancer in Milwaukee

October 2nd 2019

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.

Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer

September 29th 2019

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

Dr. Westbrook on 3-Year Follow-Up Data of the KRISTINE Trial in HER2+ Breast Cancer

September 20th 2019

Kelly E. Westbrook, MD, discusses the 3-year follow-up data on the KRISTINE trial in stage II or III HER2-positive breast cancer.

Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer Management

September 19th 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.

Fixed-Dose Subcutaneous Pertuzumab Combo Shows Noninferiority in HER2+ Breast Cancer

September 13th 2019

A fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy demonstrated noninferior pharmacokinetics compared with the standard IV infusions of the regimen in patients with HER2-positive early breast cancer, meeting the primary endpoint of the phase III FeDeriCa trial (NCT03493854).

Dr. Denduluri on the Role of Neoadjuvant Therapy in HER2+ Breast Cancer

September 12th 2019

Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.

FDA Accepts sNDA for Neratinib Combo for HER2+ Breast Cancer

September 11th 2019

The FDA has accepted a supplemental new drug application for neratinib for use in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed at least 2 prior lines of HER2-directed treatments.

Dr. Marks on PHENIX Trial Data in HER2+ Breast Cancer

September 10th 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

Novel Approaches Push the Envelope in HER2+ Breast Cancer

September 9th 2019

Douglas K. Marks, MD, discusses key developments in the HER2-positive breast cancer space and shed light on novel approaches under investigation.

Dr. Marks on the Role of TKIs in HER2-Positive Breast Cancer

September 4th 2019

Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.

Pyrotinib Combo Delays Progression in Heavily Pretreated HER2+ Breast Cancer

August 22nd 2019

Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer.